Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity-Reference-Cited by-同舟云学术

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Published:2019-07-29 Issue:22 Volume:25 Page:6662-6670
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Dagogo-Jack Ibiayi,Rooney Marguerite,Lin Jessica J.^ORCID,Nagy Rebecca J.,Yeap Beow Y.,Hubbeling Harper^ORCID,Chin Emily,Ackil Jennifer,Farago Anna F.,Hata Aaron N.,Lennerz Jochen K.^ORCID,Gainor Justin F.,Lanman Richard B.^ORCID,Shaw Alice T.

Funder

HHS | NIH | National Cancer Institute (NCI)

Conquer Cancer Foundation (CCF)

American Cancer Society (ACS)

Be A Piece of the Solution

Targeting a Cure for Lung Cancer Research

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and Mutations: Implications for Gastric Carcinogenesis and Target Therapy;Current Protein & Peptide Science;2024-09

2. The role of liquid biopsy as a catalyst for sustained progress in precision oncology – Perspective of the young committee of the international society of liquid biopsy;The Journal of Liquid Biopsy;2024-09

3. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

4. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

5. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23